CoChat
Sign Up
Cited by 177Treatment of Major DepressionNeuroscience and Neuropharmacology ResearchAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

The DOI matches its Crossref record; 205 of the 205 references it cites were found in a registry or an index.

Riluzole in the Treatment of Mood and Anxiety Disorders

Pittenger, Christopher, Coric, Vladimir, Banasr, Mounira, Bloch, Michael, Krystal, John H, Sanacora, Gerard·2008·CNS Drugs
DOI 10.2165/00023210-200822090-00004
Open this paper in CoChat — free account

Abstract

Recent advances implicate amino acid neurotransmission in the pathophysiology and treatment of mood and anxiety disorders. Riluzole, which is approved and marketed for the treatment of amyotrophic lateral sclerosis, is thought to be neuroprotective through its modulation of glutamatergic neurotransmission. Riluzole has multiple molecular actions in vitro; the two that have been documented to occur at physiologically realistic drug concentrations and are therefore most likely to be clinically relevant are inhibition of certain voltage-gated sodium channels, which can lead to reduced neurotransmitter release, and enhanced astrocytic uptake of extracellular glutamate.Although double-blind, placebo-controlled trials are lacking, several open-label trials have suggested that riluzole, either as monotherapy or as augmentation of standard therapy, reduces symptoms of obsessive-compulsive disorder, unipolar and bipolar depression, and generalized anxiety disorder. In studies of psychiatrically ill patients conducted to date, the drug has been quite well tolerated; common adverse effects include nausea and sedation. Elevation of liver function tests is common and necessitates periodic monitoring, but has been without clinical consequence in studies conducted to date in psychiatric populations. Case reports suggest utility in other conditions, including trichotillomania and self-injurious behaviour associated with borderline personality disorder. Riluzole may hold promise for the treatment of several psychiatric conditions, possibly through its ability to modulate pathologically dysregulated glutamate levels, and merits further investigation.

Overview

Integrity signals

Registry

Crossref · 10.2165/00023210-200822090-00004

Cites

205 of 205 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 205 references

Research works printed but not linked: 13

  1. Miller, 2007, Cochrane Database Syst Rev, &NA;, CD001447
  2. Wahl, 1999, Acta Neurochir Suppl, 73, 103
  3. Carlezon Jr, 2005, TINS, 28, 436
  4. Marini, 2004, Restor Neurol Neurosci, 22, 121
  5. Cluskey, 2001, Mol Path, 54, 386
  6. McShane, 2006, Cochrane Database Syst Rev, &NA;, CD003154
  7. Magistretti, 2006, JExp Biol, 209, 2304
  8. Yanagisawa, 1997, Igakuno Ayumi, 182, 851
  9. Seppi, 2001, JNeurol, 248, 866
  10. Zarate Jr, 2002, Translational Neurosci, 36, 35
  11. Goodman, 1989, Arch Gen Psychiatry, 46, 1106
  12. Stewart, 2007, Am J Med Genet B Neuropsych Genet, 144, 1028
  13. Lacomblez, 2002, Therapie, 57, 65

Cited by

Sorted by citations

See all 177

Related

Metadata

Authors
Pittenger, C., Coric, V., Banasr, M., Bloch, M., Krystal, J. H., & Sanacora, G.
Affiliations
Yale University (US)
Corresponding author
Pittenger, Christopher
ORCID
Venue
CNS Drugs
Publisher
Springer Science and Business Media LLC
Published
2008
Volume
22
Issue
9
Pages
761-786
ISSN
1172-7047 (ISSN-L)
DOI
10.2165/00023210-200822090-00004
OpenAlex
W1967308562
Cited by
177
References
205
Citations by year
2026: 5 · 2025: 6 · 2024: 5 · 2023: 12 · 2022: 7 · 2021: 11 · 2020: 6 · 2019: 6 · 2018: 7 · 2017: 10 · 2016: 17 · 2015: 12 · 2014: 9 · 2013: 13 · 2012: 13
FWCI
1.33
Type
journal article
Language
en
Open access
closed
Locations
  • CNS Drugs (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Mental Health (T32 MH 19961, T32MH019961)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
riluzole, mood disorders, anxiety disorders, obsessive-compulsive disorder, depression, bipolar disorder, generalized anxiety disorder, glutamatergic neurotransmission, voltage-gated sodium channel inhibition, neuroprotection, trichotillomania, self-harm, borderline personality disorder, drug tolerability, liver function monitoring
MeSH terms
Animals, Anxiety Disorders, Humans, Models, Biological, Nervous System Diseases, Receptors, Glutamate, Excitatory Amino Acid Antagonists, Riluzole, Mood Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review